logo-loader
Netscientific PLC

NetScientific soars as it sells stakes in Vortex Biosciences and Wanda for £150,000

The group said after the close on 22 March that it would use the proceeds of the sale towards its ongoing working capital requirements

Scientist
NetScientific had previously said it was planning to wind up the two companies

NetScientific PLC (LON:NSCI) shares soared in mid-morning trading on Monday after it sold its stakes in portfolio companies Vortex Biosciences Inc and Wanda Inc to investment firm EMV Capital Ltd for £150,000.

The group, which invests in development stage medical and healthcare businesses, said after the close on 22 March that it would use the proceeds of the sale towards its ongoing working capital requirements.

READ: NetScientific portfolio companies Vortex Biosciences and Wanda to be wound up

EMV had previously tried to acquire Vortex and Wanda earlier that week, but NetScientific had rejected the offer after concluding “the level of consideration offered is not sufficient to justify the company continuing to provide the necessary financial support to Wanda and Vortex” while it carried out due diligence and negotiations.

However, the company said the new offer with revised terms had addressed its previous concerns “satisfactorily”.

NetScientific had previously said it was planning to wind up the two companies, having held stakes of 95% and 70.8% in Vortex and Wanda respectively.

Vortex develops a liquid biopsy platform that collects circulating tumour cells (CTC) for signs of cancer, while Wanda has developed a method of remotely monitoring people with congestive heart failure and other chronic conditions.

Shares were up 33.7% at 11.7p.

--Adds share price--

Quick facts: Netscientific PLC

Price: £0.07

Market: AIM
Market Cap: £5.3 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Netscientific PLC named herein, including the promotion by the Company of Netscientific PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: ANGLE reports positive data from Parsortix FDA clinical study

Top stories from the Proactive Investors UK newsroom: ANGLE PLC (LON:AGL) has received positive results from its Parsortix FDA clinical study for metastatic breast cancer. The 400-subject clinical study will support an application for Class II regulatory clearance for Parsortix in the...

on 31/5/19

2 min read